Healthcare / BiotechnologyNasdaqCM
$5.84
-0.15 (-2.50%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-22.1M · quality 69.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
23/100
D
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$315M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-58.4%
↓Gross Margin
N/A
•Debt/Equity
0.00
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2017–2025 · 8 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.89x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-32.8M · FCF $-29.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Net Income | $-32.8M | $-32.8M | $-24.4M | $-19.4M | $-13.7M | $-13.6M | $-12.3M | $-10.6M | $-5.7M | $-4.3M |
| EBITDA | $-34.4M | $-34.4M | $-26.6M | $-21.2M | $-14.0M | — | — | — | — | — |
| EPS | -0.70 | -0.70 | -0.60 | -0.60 | -0.52 | -0.65 | — | — | — | — |
| Balance Sheet | ||||||||||
| Debt/Equity | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 | — | — | — | — | — |
| Current Ratio | 9.11 | 9.11 | — | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||
| Free Cash Flow | $-29.1M | $-29.1M | $-22.1M | $-18.8M | $-11.6M | $-12.3M | $-9.2M | $-9.1M | $-5.7M | $-3.9M |
| Returns | ||||||||||
| ROE | -58.4% | -58.4% | -60.0% | -38.0% | -43.0% | -30.9% | -47.3% | -139.8% | -33.7% | -533.2% |
| Valuation | ||||||||||
| P/B | 4.89 | 4.89 | 5.52 | 1.82 | 1.20 | — | — | — | — | — |
| Growth & Yield | ||||||||||
| EPS Growth | -16.7% | -16.7% | 0.0% | -15.4% | — | — | — | — | — | — |
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+42.1%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.60 → -0.70
Residual
+42.1%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.